UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $33.61 Million Stake in Insmed Incorporated (NASDAQ:INSM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 15.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 486,847 shares of the biopharmaceutical company's stock after purchasing an additional 63,911 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.27% of Insmed worth $33,612,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management bought a new stake in Insmed in the 4th quarter worth approximately $47,000. Smartleaf Asset Management LLC raised its position in Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the 4th quarter worth approximately $86,000.

Analyst Ratings Changes

INSM has been the subject of several research analyst reports. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. UBS Group dropped their price target on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Jefferies Financial Group initiated coverage on Insmed in a report on Tuesday, May 13th. They issued a "buy" rating and a $105.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Finally, Wells Fargo & Company raised their target price on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $96.73.

Insmed Stock Up 0.8%

NASDAQ:INSM traded up $0.52 on Friday, reaching $69.73. The stock had a trading volume of 3,625,186 shares, compared to its average volume of 2,177,885. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $53.69 and a 12-month high of $84.91. The company has a 50-day moving average of $69.77 and a 200 day moving average of $72.92. The stock has a market cap of $12.70 billion, a P/E ratio of -12.47 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the firm posted ($1.06) EPS. The business's revenue was up 22.9% compared to the same quarter last year. On average, research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,996,328.94. This represents a 5.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 4,407 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $67.81, for a total value of $298,838.67. Following the transaction, the insider now owns 92,203 shares of the company's stock, valued at approximately $6,252,285.43. This trade represents a 4.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 153,098 shares of company stock valued at $10,724,192 over the last three months. Insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.